Ganciclovir sensitivity of cytomegalovirus at diagnosis and during treatment of cytomegalovirus pneumonia in marrow transplant recipients
- PMID: 8392311
- PMCID: PMC187966
- DOI: 10.1128/AAC.37.6.1360
Ganciclovir sensitivity of cytomegalovirus at diagnosis and during treatment of cytomegalovirus pneumonia in marrow transplant recipients
Abstract
Cytomegalovirus (CMV) often persists in the lungs of marrow transplant patients with CMV pneumonia, despite ganciclovir (GCV) treatment. To determine whether GCV resistance contributes to viral persistence, the susceptibilities of CMV isolates from diagnostic bronchoalveolar lavage samples and CMV isolates obtained during treatment or from autopsy lung tissue from 12 patients were compared by DNA hybridization. Resistance (50% effective dose, > 12 microM) was detected in an isolate from only one patient who had also received several courses of GCV. GCV resistance did not explain the persistence of CMV in the lung.
Similar articles
-
Quantification of cytomegalovirus in bronchoalveolar lavage fluid after allogeneic marrow transplantation by centrifugation culture.J Clin Microbiol. 1992 Nov;30(11):2776-9. doi: 10.1128/jcm.30.11.2776-2779.1992. J Clin Microbiol. 1992. PMID: 1333478 Free PMC article.
-
Rapid detection cytomegalovirus pneumonia in recipients of bone marrow transplant: evaluation and comparison of five survey methods for bronchoalveolar lavage fluid.Bone Marrow Transplant. 1996 May;17(5):855-60. Bone Marrow Transplant. 1996. PMID: 8733709
-
Practices for cytomegalovirus diagnosis, prophylaxis and treatment in allogeneic bone marrow transplant recipients: a report from the Working Party for Infectious Diseases of the EBMT.Bone Marrow Transplant. 1993 Oct;12(4):399-403. Bone Marrow Transplant. 1993. PMID: 8275040
-
Ganciclovir. An update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients.Drugs. 1998 Jul;56(1):115-46. doi: 10.2165/00003495-199856010-00012. Drugs. 1998. PMID: 9664203 Review.
-
[Clinical, diagnostic and physiopathological aspects of cytomegalovirus pneumonia after bone marrow transplantation].Rev Pneumol Clin. 1990;46(6):244-50. Rev Pneumol Clin. 1990. PMID: 1965751 Review. French.
Cited by
-
Lack of emergence of cytomegalovirus UL97 mutations conferring ganciclovir (GCV) resistance following preemptive GCV therapy in allogeneic stem cell transplant recipients.Antimicrob Agents Chemother. 2001 Dec;45(12):3669-71. doi: 10.1128/AAC.45.12.3669-3671.2001. Antimicrob Agents Chemother. 2001. PMID: 11709367 Free PMC article. Clinical Trial.
-
How I treat resistant cytomegalovirus infection in hematopoietic cell transplantation recipients.Blood. 2016 Dec 8;128(23):2624-2636. doi: 10.1182/blood-2016-06-688432. Epub 2016 Oct 19. Blood. 2016. PMID: 27760756 Free PMC article.
-
What clinicians need to know about antiviral drugs and viral resistance.Infect Dis Clin North Am. 1997 Dec;11(4):945-67. doi: 10.1016/s0891-5520(05)70399-8. Infect Dis Clin North Am. 1997. PMID: 9421709 Free PMC article. Review.
-
Resistance of human cytomegalovirus to antiviral drugs.Clin Microbiol Rev. 1999 Apr;12(2):286-97. doi: 10.1128/CMR.12.2.286. Clin Microbiol Rev. 1999. PMID: 10194460 Free PMC article. Review.
-
High-dose acyclovir and pre-emptive ganciclovir to prevent cytomegalovirus disease in myeloablative and non-myeloablative allogeneic stem cell transplantation.Bone Marrow Transplant. 2002 Aug;30(4):235-42. doi: 10.1038/sj.bmt.1703648. Bone Marrow Transplant. 2002. PMID: 12203140 Free PMC article. Clinical Trial.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical